Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study With Meropenem

Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study... Downloaded from http://journals.lww.com/americantherapeutics by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 American Journal of Therapeutics 0, 1–3 (2020) Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study With Meropenem To the Editor: was predefined in 0.2, and we used a ratio of 1:1 to In the past decade, polymyxin B and colistin have optimize balance and precision. been the most important options for the treatment of Bivariate analysis was performed separately for 1 2 carbapenem-resistant Enterobacteriaceae infections. each variable. P values were calculated using the x However, the pharmacokinetic profile and the high test or Fisher exact test for categorical variables and nephrotoxicity are the main limitations of polymyx- Student t test for continuous variables. The multivari- 2,3 ins. Amikacin has been an option in some hospitals able model was performed with the intent to identify for the treatment of carbapenem-resistant bacteria. independent risk factors apart from our main interest New studies evaluating amikacin dose in critical pa- in this study (amikacin vs. meropenem). All tests tients have been recently published. The challenge is were 2-tailed, and a P value #0.05 was considered that some physicians are reluctant to prescribe high significant. Statistical analyses were performed using doses http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Therapeutics Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/acute-kidney-injury-in-patients-using-amikacin-in-intensive-care-unit-W2ToSnP8kj

References (10)

Publisher
Wolters Kluwer Health
ISSN
1075-2765
eISSN
1536-3686
DOI
10.1097/MJT.0000000000000955
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/americantherapeutics by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 American Journal of Therapeutics 0, 1–3 (2020) Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study With Meropenem To the Editor: was predefined in 0.2, and we used a ratio of 1:1 to In the past decade, polymyxin B and colistin have optimize balance and precision. been the most important options for the treatment of Bivariate analysis was performed separately for 1 2 carbapenem-resistant Enterobacteriaceae infections. each variable. P values were calculated using the x However, the pharmacokinetic profile and the high test or Fisher exact test for categorical variables and nephrotoxicity are the main limitations of polymyx- Student t test for continuous variables. The multivari- 2,3 ins. Amikacin has been an option in some hospitals able model was performed with the intent to identify for the treatment of carbapenem-resistant bacteria. independent risk factors apart from our main interest New studies evaluating amikacin dose in critical pa- in this study (amikacin vs. meropenem). All tests tients have been recently published. The challenge is were 2-tailed, and a P value #0.05 was considered that some physicians are reluctant to prescribe high significant. Statistical analyses were performed using doses

Journal

American Journal of TherapeuticsWolters Kluwer Health

Published: Jan 1, 2020

There are no references for this article.